

# Human PILRA Protein

Cat. No. PRA-HM201

## Description

<b>Source</b>	Recombinant Human PILRA Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Gln20-Ala197.
<b>Accession</b>	Q9UKJ1-1
<b>Molecular Weight</b>	The protein has a predicted MW of 47 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result.
<b>Endotoxin</b>	Less than 1EU per $\mu\text{g}$ by the LAL method.
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

## Formulation and Storage

<b>Formulation</b>	Supplied as 0.22 $\mu\text{m}$ filtered solution in PBS (pH 7.4).
<b>Storage</b>	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognitive performance; Mild Cognitive Impairment (MCI) is instead an objective decline in cognitive performance that does not reach pathology. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a cell surface inhibitory receptor that was recently suggested to be involved in AD pathogenesis. In particular, the arginine-to-glycine substitution in position 78 (R78, rs1859788) was shown to be protective against AD.

## Assay Data


### Bis-Tris PAGE



Human PILRA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC

Assay Data



The purity of Human PILRA is greater than 95% as determined by SEC-HPLC.